Identification of anti-inflammatory fractions of Geranium wilfordii using tumor necrosis factor-alpha as a drug target on Herbochip® – an array-based high throughput screening platform
Open Access
- 12 May 2015
- journal article
- research article
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 15 (1) , 1-11
Abstract
Geranium wilfordii is one of the major species used as Herba Geranii (lao-guan-cao) in China, it is commonly used solely or in polyherbal formulations for treatment of joint pain resulted from rheumatoid arthritis (RA) and gout. This herb is used to validate a target-based drug screening platform called Herbochip® and evaluate anti-inflammatory effects of Geranium wilfordii ethanolic extract (GWE) using tumor necrosis factor-alpha (TNF-α) as a drug target together with subsequent in vitro and in vivo assays. A microarray-based drug screening platform was constructed by arraying HPLC fractions of herbal extracts onto a surface-activated polystyrene slide (Herbochip®). Using TNF-α as a molecular probe, fractions of 82 selected herbal extracts, including GWE, were then screened to identify plant extracts containing TNF-α-binding agents. Cytotoxicity of GWE and modulatory effects of GWE on TNF-α expression were evaluated by cell-based assays using TNF-α sensitive murine fibrosarcoma L929 cells as an in vitro model. The in vivo anti-inflammatory effects of GWE were further assessed by animal models including carrageenan-induced hind paw edema in rats and xylene-induced ear edema in mice, in comparison with aspirin. The hybridization data obtained by Herbochip® analysis showed unambiguous signals which confirmed TNF-α binding activity in 46 herbal extracts including GWE. In L929 cells GWE showed significant inhibitory effect on TNF-α expression with negligible cytotoxicity. GWE also significantly inhibited formation of carrageenan-induced hind paw edema and xylene-induced ear edema in animal models, indicating that it indeed possessed anti-inflammatory activity. We have thus validated effectiveness of the Herbochip® drug screening platform using TNF-α as a molecular target. Subsequent experiments on GWE lead us to conclude that the anti-RA activity of GWE can be attributed to inhibitory effect of GWE on the key inflammatory factor, TNF-α. Our results contribute towards validation of the traditional use of GWE in the treatment of RA and other inflammatory joint disorders.Keywords
This publication has 21 references indexed in Scilit:
- Rheumatoid arthritis: From autoimmunity to synovitis and joint destructionJournal of Autoimmunity, 2012
- Treatment of ankylosing spondylitis in patients refractory to TNF-inhibitionCurrent Opinion in Rheumatology, 2012
- Nutraceuticals and botanicals: overview and perspectivesInternational Journal of Food Sciences and Nutrition, 2012
- Estimation of antinociceptive and anti-inflammatory activity on Geranium pratense subsp. finitimum and its phenolic compoundsJournal of Ethnopharmacology, 2007
- Tumor Necrosis Factor Inhibitors for Rheumatoid ArthritisNew England Journal of Medicine, 2006
- Artemisinins: mechanisms of action and potential for resistanceDrug Resistance Updates, 2004
- Artemisinins target the SERCA of Plasmodium falciparumNature, 2003
- Inhibition of LPS‐induced nitric oxide and TNF‐α production by α‐lipoic acid in rat Kupffer cells and in RAW 264.7 murine macrophagesImmunology & Cell Biology, 2002
- The Persuasive Appeal of Alternative MedicineAnnals of Internal Medicine, 1998
- Trends in Alternative Medicine Use in the United States, 1990-1997JAMA, 1998